BMO Capital on CRISPR Therapeutics (CRSP): 'We Continue to Highlight the Large Oppty of FXI Space'
Tweet Send to a Friend
BMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $75.00 price target on CRISPR Therapeutics (NASDAQ: CRSP).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
